# A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations

> **NCT03822546** · NA · COMPLETED · sponsor: **Fontem Ventures BV** · enrollment: 15 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **OTHER:** Conventional cigarette
- **OTHER:** myblu 25 mg freebase
- **OTHER:** myblu 16 mg nicotine salt
- **OTHER:** myblu 25 mg nicotine salt
- **OTHER:** myblu 40 mg nicotine salt
- **OTHER:** blu PRO 48 mg nicotine salt

## Key facts

- **NCT ID:** NCT03822546
- **Lead sponsor:** Fontem Ventures BV
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822546, "A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03822546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*